3NF3 image
Deposition Date 2010-06-09
Release Date 2010-07-21
Last Version Date 2023-11-22
Entry Detail
PDB ID:
3NF3
Title:
Crystal structure of BoNT/A LC with JTH-NB-7239 peptide
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.40 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 21 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:BoNT/A
Gene (Uniprot):a
Chain IDs:A
Chain Length:425
Number of Molecules:1
Biological Source:Clostridium botulinum
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
AIB B ALA ALPHA-AMINOISOBUTYRIC ACID
Peptide-like Molecules
PRD_000997
Primary Citation
Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.
Plos One 5 e11378 e11378 (2010)
PMID: 20614028 DOI: 10.1371/journal.pone.0011378

Abstact

The botulinum neurotoxin serotype A light chain (BoNT/A LC) protease is the catalytic component responsible for the neuroparalysis that is characteristic of the disease state botulism. Three related peptide-like molecules (PLMs) were designed using previous information from co-crystal structures, synthesized, and assayed for in vitro inhibition against BoNT/A LC. Our results indicate these PLMS are competitive inhibitors of the BoNT/A LC protease and their K(i) values are in the nM-range. A co-crystal structure for one of these inhibitors was determined and reveals that the PLM, in accord with the goals of our design strategy, simultaneously involves both ionic interactions via its P1 residue and hydrophobic contacts by means of an aromatic group in the P2' position. The PLM adopts a helical conformation similar to previously determined co-crystal structures of PLMs, although there are also major differences to these other structures such as contacts with specific BoNT/A LC residues. Our structure further demonstrates the remarkable plasticity of the substrate binding cleft of the BoNT/A LC protease and provides a paradigm for iterative structure-based design and development of BoNT/A LC inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures